GlassScriptPhysician profile
Steven H Epstein
NPI 1811173636
$7,020.15
in general payments reported to CMS, 2019-2025
33 companies · $637 in 2025
The $637 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,301 · 2020: $624 · 2021: $1,016 · 2022: $1,426 · 2023: $1,122 · 2024: $894 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,639 · Education: $13.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,639.11 |
| Education | $13.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,406.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,079.34 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $797.41 | 2019-2024 | Xifaxan, Relistor |
| Janssen Biotech, INC. | $406.16 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $258.56 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $206.23 | 2020-2024 | Linzess |
| Merck Sharp & Dohme LLC | $167.02 | 2019-2023 | Dificid, Zinplava |
| Qol Medical, LLC | $137.71 | 2019-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $136.51 | 2022-2025 | Dupixent |
| Genzyme Corporation | $134.67 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $132.18 | 2019-2023 | Ocaliva |
| Celgene Corporation | $130.23 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $120.64 | 2020-2022 | |
| Amgen INC. | $99.54 | 2021-2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $90.41 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $89.54 | 2019-2020 | |
| Evoke Pharma, INC. | $87.37 | 2021-2025 | Gimoti |
| Braintree Laboratories, INC. | $79.70 | 2019-2023 | Sutab |
| Ardelyx, INC. | $58.40 | 2022-2024 | Ibsrela |
| Ucb, INC. | $50.36 | 2019-2020 | |
| Lilly USA, LLC | $49.53 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $39.78 | 2019 | |
| Boston Scientific Corporation | $37.19 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Janssen Scientific Affairs, LLC | $35.25 | 2024 | Tremfya |
| Alnylam Pharmaceuticals INC. | $34.36 | 2024-2025 | Givlaari |
| Aimmune Therapeutics, INC. | $32.90 | 2023 | |
| Fresenius Kabi USA, LLC | $28.34 | 2023 | |
| Medtronic, INC. | $20.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.71 | 2023 | Cyltezo |
| Capsovision, INC. | $14.72 | 2024 | Capsocam Plus |
| Horizon Therapeutics Plc | $13.86 | 2021 | |
| Celltrion USA INC. | $13.50 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.